Single-cell RNA-seq Drug Response Prediction via Bulk Data Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current computational tools for predicting drug response at the single-cell level face challenges due to differences between bulk and single-cell RNA-seq data, low detection rates, and stochastic drop-outs, leading to unreliable predictions.
Innovation Solution
The method integrates single-cell RNA-seq data with bulk RNA-seq data from cancer cell lines using canonical correlation analysis to capture shared gene expression patterns, allowing for the prediction of cellular drug response scores.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If bulk RNA-seq data is used to predict drug response, then average expression across cells is obtained, but cell type and composition information is obscured
Solution Approach 1:
The patent segments bulk RNA-seq data into cell-type-specific expression profiles by integrating with scRNA-seq data. The method decomposes the bulk expression matrix into contributions from different cell types using reference scRNA-seq data, thereby recovering cell-type-specific information that was obscured in the bulk measurement.
Solution Approach 2:
The patent uses scRNA-seq data as an intermediary to transfer drug response information to bulk RNA-seq data. By establishing a mapping between bulk and single-cell expression spaces through canonical correlation analysis, the method enables bulk data to predict drug response at single-cell resolution without directly measuring single-cell drug responses.
2Measurement precision
If single-cell RNA-seq data is used for drug response prediction, then cell-level gene expression patterns are captured, but low detection rates and stochastic drop-outs reduce prediction reliability
Solution Approach 1:
The patent merges bulk RNA-seq data with scRNA-seq data to create a hybrid prediction system. Bulk RNA-seq data provides robust average expression measurements that can compensate for drop-outs in scRNA-seq data, while scRNA-seq data provides cell-type-specific information. The integration through canonical correlation analysis combines the strengths of both data types to improve prediction reliability.
Solution Approach 2:
The method uses feedback from bulk RNA-seq data to correct and refine predictions made from scRNA-seq data. The bulk data serves as a reference that provides stable signal for genes with low detection rates in single-cell data, allowing the model to adjust predictions based on the more reliable bulk measurements.
3Measurement precision
If computational tools integrate bulk and single-cell RNA-seq data, then drug response prediction accuracy is improved, but data integration complexity increases
Solution Approach 1:
The patent transforms the data integration problem by changing the parameter space through canonical correlation analysis. Instead of directly integrating expression values from bulk and scRNA-seq data, the method finds linear combinations of genes (canonical variables) that maximize correlation between the two data types, thereby simplifying the integration process while preserving predictive information.
Data Source
AI summary
Methods for facilitating drug discovery in various models and proposing single cell-type-specific drug candidates, and predicting cellular drug sensitivities. Predictions comprise obtaining bulk RNA sequence data, wherein bulk RNA seq data is pan-cancer cell line transcriptomic data from one or more sources; obtaining single cell RNA sequence data (scRNA-seq) from one or more sources; integrating the bulk RNA sequence data and scRNA-seq data; capturing similarities between the bulk data and the scRNA-seq data based on a shared drug response relative gene and using canonical correlation analysis; extracting one or more drug-response relevant features and selecting a pharmacogenomic subspace for accurately predicting a single-cell drug response.